Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Mercy Cancer Center at Mercy Medical Center
102
mi
from 43215
Canton, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Mercy Cancer Center at Mercy Medical Center
102
mi
from 43215
Canton, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Aultman Hospital
102
mi
from 43215
Canton, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Aultman Hospital
102
mi
from 43215
Canton, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Case Western Reserve Univ
129
mi
from 43215
Cleveland, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
129
mi
from 43215
Cleveland, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Metro Health Medical Center
123
mi
from 43215
Cleveland, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Metro Health Medical Center
123
mi
from 43215
Cleveland, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
St. Rita's Medical Center
78
mi
from 43215
Lima, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
St. Rita's Medical Center
78
mi
from 43215
Lima, OH
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Natalie W Bryant Cancer Center
752
mi
from 43215
Tulsa, OK
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Natalie W Bryant Cancer Center
752
mi
from 43215
Tulsa, OK
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Bryn Mawr Hospital
407
mi
from 43215
Bryn Mawr, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Bryn Mawr Hospital
407
mi
from 43215
Bryn Mawr, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Geisinger Medical Center
344
mi
from 43215
Danville, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Geisinger Medical Center
344
mi
from 43215
Danville, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Geisinger Cancer Center
376
mi
from 43215
Hazelton, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Geisinger Cancer Center
376
mi
from 43215
Hazelton, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Paoli Memorial Hospital
398
mi
from 43215
Paoli, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Paoli Memorial Hospital
398
mi
from 43215
Paoli, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Geisinger Medical Group - State College
278
mi
from 43215
State College, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Geisinger Medical Group - State College
278
mi
from 43215
State College, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Geisinger Wyoming Valley Medical Center
385
mi
from 43215
Wilkes-Barre, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Geisinger Wyoming Valley Medical Center
385
mi
from 43215
Wilkes-Barre, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
CCOP - Main Line Health
410
mi
from 43215
Wynnewood, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
CCOP - Main Line Health
410
mi
from 43215
Wynnewood, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Lankenau Cancer Center at Lankenau Hospital
410
mi
from 43215
Wynnewood, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Lankenau Cancer Center at Lankenau Hospital
410
mi
from 43215
Wynnewood, PA
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Parkland Health & Hospital Systems
911
mi
from 43215
Dallas, TX
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Parkland Health & Hospital Systems
911
mi
from 43215
Dallas, TX
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
910
mi
from 43215
Dallas, TX
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
910
mi
from 43215
Dallas, TX
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Dean Medical Center - Madison
398
mi
from 43215
Madison, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Dean Medical Center - Madison
398
mi
from 43215
Madison, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Oconomowoc Memorial Hospital
356
mi
from 43215
Oconomowoc, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Oconomowoc Memorial Hospital
356
mi
from 43215
Oconomowoc, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Waukesha Memorial Hospital
343
mi
from 43215
Waukesha, WI
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Waukesha Memorial Hospital
343
mi
from 43215
Waukesha, WI
Photodynamic Therapy (PDT) in Lung Cancer
An Evaluation of the Effectiveness of Photodynamic Therapy (PDT) Compared to Surgical Resection in Early Stage Roentgenographically Occult Lung Cancer.
Status: Archived
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Photodynamic Therapy (PDT) in Lung Cancer
An Evaluation of the Effectiveness of Photodynamic Therapy (PDT) Compared to Surgical Resection in Early Stage Roentgenographically Occult Lung Cancer.
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Hardin Memorial Hosptial
218
mi
from 43215
Elizabethtown, KY
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Hardin Memorial Hosptial
218
mi
from 43215
Elizabethtown, KY
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
The Jones Clinic - Germantown
501
mi
from 43215
Germantown, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
The Jones Clinic - Germantown
501
mi
from 43215
Germantown, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Jackson-Madison County Hospital
436
mi
from 43215
Jackson, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Jackson-Madison County Hospital
436
mi
from 43215
Jackson, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Baptist Regional Cancer Center at Baptist Riverside
275
mi
from 43215
Knoxville, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Baptist Regional Cancer Center at Baptist Riverside
275
mi
from 43215
Knoxville, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
346
mi
from 43215
Franklin, TN
Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
346
mi
from 43215
Franklin, TN
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
1645
mi
from 43215
Scottsdale, AZ
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1645
mi
from 43215
Scottsdale, AZ
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Memorial Hospital of Rhode Island
621
mi
from 43215
Pawtucket, RI
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Memorial Hospital of Rhode Island
621
mi
from 43215
Pawtucket, RI
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
993
mi
from 43215
Miami, FL
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
993
mi
from 43215
Miami, FL
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
2027
mi
from 43215
Portland, OR
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2027
mi
from 43215
Portland, OR
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer
Status: Archived
Rochester General Hospital
357
mi
from 43215
Rochester, NY
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Rochester General Hospital
357
mi
from 43215
Rochester, NY
Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Assessing Hypoxia by 18F-EF5 PET Scanning and Glycolysis by 18FFDG PET Scanning in Subjects With Non-Small Cell Lung Cancer
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Assessing Hypoxia by 18F-EF5 PET Scanning and Glycolysis by 18FFDG PET Scanning in Subjects With Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
Immunotoxin Therapy, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase I Trial of SS1 ( dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Status: Archived
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Immunotoxin Therapy, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
A Phase I Trial of SS1 ( dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
322
mi
from 43215
Bethesda, MD
Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
Status: Archived
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Status: Archived
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Breathing Synchronized PET/CT Scans for the Detection of Lung Lesions and Assessment of Tumor Glycolysis
The Use of Breathing Synchronized PET/CT Scans for the Detection of Lung Lesions and Assessment of Tumor Glycolysis
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
Breathing Synchronized PET/CT Scans for the Detection of Lung Lesions and Assessment of Tumor Glycolysis
The Use of Breathing Synchronized PET/CT Scans for the Detection of Lung Lesions and Assessment of Tumor Glycolysis
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
OS09328 Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
Status: Archived
University of Wisconsin-Madison, Department of Dermatology
393
mi
from 43215
Madison, WI
Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
OS09328 Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison, Department of Dermatology
393
mi
from 43215
Madison, WI
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
A Phase I Dose Escalation Study of RAD001 in Combination With Chemotherapy and Radiation in Patients With NSCLC
Status: Archived
University of Chicago Medical Center
270
mi
from 43215
Chicago, IL
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
A Phase I Dose Escalation Study of RAD001 in Combination With Chemotherapy and Radiation in Patients With NSCLC
Status: Archived
Updated: 1/1/1970
University of Chicago Medical Center
270
mi
from 43215
Chicago, IL
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Hematology Oncology Associates of the Quad Cities
405
mi
from 43215
Bettendorf, IA
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
405
mi
from 43215
Bettendorf, IA
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
A Pilot, Phase II , Open Label, Nonrandomized, Multi- Center Study of [F 18]HX4 Positron Emission Tomography (PET) to Detect Hypoxia in Tumors
Status: Archived
Holy Name Medical Center
477
mi
from 43215
Teaneck, NJ
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors
A Pilot, Phase II , Open Label, Nonrandomized, Multi- Center Study of [F 18]HX4 Positron Emission Tomography (PET) to Detect Hypoxia in Tumors
Status: Archived
Updated: 1/1/1970
Holy Name Medical Center
477
mi
from 43215
Teaneck, NJ
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
346
mi
from 43215
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
346
mi
from 43215
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderiblt University Medical Center
335
mi
from 43215
Nashville, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderiblt University Medical Center
335
mi
from 43215
Nashville, TN
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy
Status: Archived
Dana-Farber / Harvard Cancer Center
643
mi
from 43215
Boston, MA
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
643
mi
from 43215
Boston, MA
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy
Status: Archived
Clinical Research Facility
993
mi
from 43215
Miami, FL
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
993
mi
from 43215
Miami, FL